Monte S. Willis;Thais M. Sielecki-Dzurdz;Brett P. Giroir;Vidal F. De La Cruz, Jr.
发明人:
Brett P. Giroir,Monte S. Willis,Vidal F. De La Cruz, Jr.,Thais M. Sielecki-Dzurdz
申请号：
US11932909
公开号：
US08747843B2
申请日:
2007.10.31
申请国别(地区):
US
年份:
2014
代理人:
摘要：
One embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-MIF antibody； and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount at least one anti-CD74 antibody； and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-TNFR antibody； a therapeutically effective amount of at least one anti-MIF antibody； and at least one pharmaceutically acceptable carrier. Other embodiments of the present invention relate to methods of treating or preventing cardiac dysfunction, cardiodepression, burn injury-associated cardiac dysfunction, improving cardiac function in a subject following acute myocardial infarction, and identifying an MIF inhibitor.
